Select Page

Grifols’s Prolastina approved for use in Denmark

Jan 29, 2020 | News

The Alpha-1 Foundation is proud to report that multinational pharmaceutical manufacturer Grifols also received approval by the Danish Medicines Council for Prolastina, a plasma-derived drug used for augmentation therapy.

The Danish Medicines Council, citing a reasonable relationship between the value of the drug and the cost of treatment, recommended that human alpha-1 antitrypsin plasma-based therapy become the standard treatment for severe Alpha-1 Antitrypsin Deficiency (AATD). The Council approved two products for treatment: Respreeza® and Prolastina.

Based on the recent publication from the Health Policy Journal (Sundhedspolitisk Tidsskrift) and the Danish Medicines Council, the following information was communicated to the global community:

The recommendation is applicable to patients who have progressive emphysema and documented smoking cessation that must be present for at least six months prior to initiation of treatment, as well as progressive emphysema when detected by CT scan has documented emphysema with concomitant pulmonary function.

Treatment requires an annual reassessment, and is discontinued if the patient meets any of the following criteria:

  • receives a single or double lung transplant.
  • terminal diagnosis is assessed, and continued treatment is therefore deemed futile or too demanding for the patient.
  • resumes smoking. This can be checked by carbon monoxide measurement prior to each injection patients being treated in hospital. For patients who self-administer treatment at home, for example, cotinine measurement every 6 months can be used.
  • is not considered to have sufficient effect on the treatment. Loss of lung density of more than 30g / L within 10 years of treatment should cease treatment

Alpha-1 antitrypsin is derived from human plasma and is given to increase the plasma concentration of alpha-1 antitrypsin in patients with severe Alpha-1 Antitrypsin Deficiency and evidence of progressive emphysema. The treatment is given to delay the development of emphysema and the drug is given as maintenance treatment and at 60 mg/kg body weight once weekly by intravenous infusion.

Source: Sundhedspolitisk Tidsskrift and The Medicines Council

Alpha-1 Events Calendar

January

February 2020

March
S
M
T
W
T
F
S
26
27
28
29
30
31
1
Events for February

1st

2
3
4
5
6
7
8
Events for February

2nd

No Events
Events for February

3rd

No Events
Events for February

4th

Events for February

5th

No Events
Events for February

6th

No Events
Events for February

7th

No Events
Events for February

8th

9
10
11
12
13
14
15
Events for February

9th

No Events
Events for February

10th

No Events
Events for February

11th

No Events
Events for February

12th

Events for February

13th

No Events
Events for February

14th

No Events
Events for February

15th

16
17
18
19
20
21
22
Events for February

16th

No Events
Events for February

17th

No Events
Events for February

18th

No Events
Events for February

19th

No Events
Events for February

20th

No Events
Events for February

21st

No Events
Events for February

22nd

23
24
25
26
27
28
29
Events for February

23rd

No Events
Events for February

24th

No Events
Events for February

25th

No Events
Events for February

26th

No Events
Events for February

27th

Events for February

28th

Events for February

29th

1
2
3
4
5
6
7